Please login to the form below
Listeria monocytogenes
This page shows the latest Listeria monocytogenes news and features for those working in and with pharma, biotech and healthcare.
Advaxis shaken by another FDA hold on cervical cancer vaccine
Axal is a targeted Listeria monocytogenes (Lm)-based immunotherapy that attacks HPV-associated cancers by altering a live strain of Lm bacteria to generate cancer-fighting T cells against cancer antigens
Latest news
-
Amgen enters into $540m immunotherapy collaboration
Listeria monocytogenes (Lm) technology to create a tailored cancer treatment.
-
Listeria-based vaccine could halt breast cancer
The vaccine was developed from investigations into the Listeria monocytogenes bacterium which grows in milk, cheese and other dairy products. ... Listeria blocks the immune system's response when it gains access to the body, helping it to spread.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Pharma deals during October 2014
on Aduro's novel LADD [live-attenuated double-deleted Listeria monocytogenes strains that have been engineered to induce an innate immune response] immunotherapy platform.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
